How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Draft guidance consultation

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about bulevirtide

    Marketing authorisation indication

    2.1 Bulevirtide (Hepcludex, Gilead) has a conditional marketing authorisation 'for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV RNA positive adult patients with compensated liver disease'.

    Dosage in the marketing authorisation

    2.2 The dosage schedule is available in the summary of product characteristics for bulevirtide.

    Price

    2.3 The list price of bulevirtide is currently confidential. The company has a commercial arrangement, which would have applied if the technology had been recommended.